Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
3180 Porter Drive
Palo Alto, CA 94304
Phone: (650) 496 3777Website: https://www.jazzpharma.com/Careers: careers.jazzpharma.com/jobsPatient Assistance Program: www.jazzpharma.com/responsibility...
Latest news
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
18 November 2022 - Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
12 August 2021 - FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
30 June 2021 - Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
30 March 2021 - FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
22 July 2020 - Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
22 January 2020 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
20 March 2019 - Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
21 December 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
3 December 2018 - Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
2 March 2018
Drugs Associated with Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc manufactures, markets and/or distributes more than 11 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Defitelio
Generic name: defibrotide Drug class: miscellaneous coagulation modifiers |
||
|
Erwinaze
Generic name: asparaginase erwinia chrysanthemi Drug class: miscellaneous antineoplastics |
||
|
FazaClo
Generic name: clozapine Drug class: atypical antipsychotics |
||
|
Prialt
Generic name: ziconotide Drug class: miscellaneous analgesics |
12 reviews | 4.0 / 10 |
|
Rylaze
Generic name: asparaginase erwinia chrysanthemi Drug class: miscellaneous antineoplastics |
||
|
Sunosi
Generic name: solriamfetol Drug class: miscellaneous central nervous system agents |
62 reviews | 4.6 / 10 |
|
Versacloz
Generic name: clozapine Drug class: atypical antipsychotics |
||
|
Vyxeos
Generic name: cytarabine liposomal/daunorubicin liposomal Drug class: antineoplastic combinations |
||
|
Xyrem
Generic name: sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
104 reviews | 7.7 / 10 |
|
Xywav
Generic name: calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
9 reviews | 7.0 / 10 |
|
Zepzelca
Generic name: lurbinectedin Drug class: alkylating agents |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||